BioLife Solutions (NASDAQ:BLFS) Downgraded to Sell at ValuEngine

BioLife Solutions (NASDAQ:BLFS) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday, ValuEngine reports.

A number of other analysts have also recently weighed in on BLFS. Maxim Group set a $26.00 target price on shares of BioLife Solutions and gave the stock a “buy” rating in a report on Tuesday, September 17th. Northland Securities raised their target price on shares of BioLife Solutions from $18.00 to $22.00 and gave the stock an “outperform” rating in a report on Wednesday, September 4th. BidaskClub upgraded shares of BioLife Solutions from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 7th. Zacks Investment Research lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Finally, HC Wainwright started coverage on shares of BioLife Solutions in a research note on Monday, July 22nd. They issued a “buy” rating and a $23.00 price objective for the company. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. BioLife Solutions presently has a consensus rating of “Buy” and an average target price of $18.40.

NASDAQ:BLFS traded down $0.48 during trading hours on Thursday, reaching $14.77. 180,000 shares of the company’s stock were exchanged, compared to its average volume of 175,961. The company has a market capitalization of $301.67 million, a P/E ratio of 105.50 and a beta of 1.35. BioLife Solutions has a 12 month low of $9.15 and a 12 month high of $22.44. The company has a quick ratio of 7.71, a current ratio of 6.49 and a debt-to-equity ratio of 0.01. The business’s 50-day simple moving average is $16.36 and its two-hundred day simple moving average is $17.71.

In related news, VP James Mathers sold 2,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $20.06, for a total value of $50,150.00. Following the completion of the transaction, the vice president now owns 19,884 shares of the company’s stock, valued at approximately $398,873.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Johan Wedell-Wedellsborg sold 17,243 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $27.00, for a total transaction of $465,561.00. Insiders sold a total of 195,794 shares of company stock valued at $3,629,637 in the last ninety days. Company insiders own 27.00% of the company’s stock.

A number of institutional investors have recently bought and sold shares of BLFS. FMR LLC acquired a new stake in shares of BioLife Solutions during the 1st quarter valued at $2,684,000. WINTON GROUP Ltd boosted its stake in shares of BioLife Solutions by 26.3% during the 2nd quarter. WINTON GROUP Ltd now owns 22,118 shares of the medical equipment provider’s stock valued at $375,000 after buying an additional 4,607 shares during the period. Penbrook Management LLC acquired a new stake in shares of BioLife Solutions during the 2nd quarter valued at $493,000. Roubaix Capital LLC boosted its stake in shares of BioLife Solutions by 165.9% during the 2nd quarter. Roubaix Capital LLC now owns 120,313 shares of the medical equipment provider’s stock valued at $2,039,000 after buying an additional 75,068 shares during the period. Finally, Alpine Woods Capital Investors LLC acquired a new stake in shares of BioLife Solutions during the 2nd quarter valued at $170,000. 46.22% of the stock is owned by hedge funds and other institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Further Reading: How to invest using market indexes

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.